Vaccination Phase 3

Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.

Dr Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18

Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman and Managing Director of Bharat Biotech, Krishna Ella said.

After the company submitted safety, immunogenicity and efficacy data, the Subject Expert Committee granted permission for conducting the trials in India.

South Africa on Friday joined the international Phase 3 clinical trials of China's Sinovac Biotech COVID-19 vaccine for those aged between 6 months and 17 years, with first of the 2,000 children receiving their jabs.

Recruitment of volunteers for the phase 2/3 clinical trial of COVID-19 vaccine Covovax among children aged 2 to 17 years began on Sunday at the Hamdard Institute of Medical Sciences and Research In Delhi.

BBV154, developed by Bharat Biotech, is India's first intranasal vaccine to receive regulatory nod for late-stage clinical trials from the Biotechnology Industry Research Assistance Council's (BIRAC) under the Department of Biotechnology.

An expert panel of the Central Drugs Standard Control Organisation today recommended granting permission to Serum Institute of India (SII) for conducting phase 2/3 trials of Covovax on children aged 2 to 17 years with certain conditions, sources said

Bharat Biotech's Covaxin is overall 77.8 per cent effective "against symptomatic COVID-19", the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed.

A government expert panel has said that Sputnik Light can submit Phase 3 trial data for the single-dose Sputnik Light COVID-19 vaccine in India, its India-partner Dr Reddy's said on Thursday, hours after reports said they had been denied approval for

Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.

Bharat Biotech has submitted Phase III trial data for the Covaxin coronavirus vaccine to the DCGI (Drug Controller General of India), whose SEC (subject expert committee) is expected to meet later today - likely around noon.

Once the results of Covaxin's phase 3 trials are out in July, its manufacturers have scheduled a phase 4 trial to test the vaccines real-world effectiveness, Bharat Biotech said today.

Russian scientists leading clinical studies for the Sputnik V COVID-19 vaccine have responded to claims of "serious concerns over interim results from phase 3 trials" by stressing their data meets "clear and transparent standards..."

Covaxin trials on children from two to 18 years were cleared by the Drugs Controller General of India (DCGI) today. This is the first time in India that a Covid vaccine will be tested on children.

Bharat Biotech has sought the Drug Controller General of India's approval to conduct phase-3 trials of its intranasal vaccine (BBV154) against Covid to be used as a booster dose, sources said on Monday.

Dr Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18

Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman and Managing Director of Bharat Biotech, Krishna Ella said.

After the company submitted safety, immunogenicity and efficacy data, the Subject Expert Committee granted permission for conducting the trials in India.

South Africa on Friday joined the international Phase 3 clinical trials of China's Sinovac Biotech COVID-19 vaccine for those aged between 6 months and 17 years, with first of the 2,000 children receiving their jabs.

Recruitment of volunteers for the phase 2/3 clinical trial of COVID-19 vaccine Covovax among children aged 2 to 17 years began on Sunday at the Hamdard Institute of Medical Sciences and Research In Delhi.

BBV154, developed by Bharat Biotech, is India's first intranasal vaccine to receive regulatory nod for late-stage clinical trials from the Biotechnology Industry Research Assistance Council's (BIRAC) under the Department of Biotechnology.

An expert panel of the Central Drugs Standard Control Organisation today recommended granting permission to Serum Institute of India (SII) for conducting phase 2/3 trials of Covovax on children aged 2 to 17 years with certain conditions, sources said

Bharat Biotech's Covaxin is overall 77.8 per cent effective "against symptomatic COVID-19", the vaccine maker said today in a statement, citing the data from the third phase of clinical trials. The data, however, is yet to be peer-reviewed.

A government expert panel has said that Sputnik Light can submit Phase 3 trial data for the single-dose Sputnik Light COVID-19 vaccine in India, its India-partner Dr Reddy's said on Thursday, hours after reports said they had been denied approval for

Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.

Bharat Biotech has submitted Phase III trial data for the Covaxin coronavirus vaccine to the DCGI (Drug Controller General of India), whose SEC (subject expert committee) is expected to meet later today - likely around noon.

Once the results of Covaxin's phase 3 trials are out in July, its manufacturers have scheduled a phase 4 trial to test the vaccines real-world effectiveness, Bharat Biotech said today.

Russian scientists leading clinical studies for the Sputnik V COVID-19 vaccine have responded to claims of "serious concerns over interim results from phase 3 trials" by stressing their data meets "clear and transparent standards..."

Covaxin trials on children from two to 18 years were cleared by the Drugs Controller General of India (DCGI) today. This is the first time in India that a Covid vaccine will be tested on children.